Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug-resistant typhoid in kids: does a two-drug combo speed up recovery?

NCT ID NCT07445282

Disease control Sponsor: Sheikh Zayed Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving two antibiotics together (meropenem and azithromycin) helps children with drug-resistant typhoid fever get better faster than using just one. 90 children aged 6 months to 5 years with confirmed typhoid took part. The main goal was to see how quickly their fever went away and stayed away for at least 48 hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

90 people

The number who actually took part.

Started

May 2025

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 4 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 6 months to under 5 years * Blood culture-confirmed extensively drug-resistant Salmonella Typhi infection * Axillary temperature ≥100°F * Uncomplicated typhoid fever Exclusion Criteria: * Complicated typhoid fever (intestinal perforation, gastrointestinal bleeding, encephalopathy, or shock) * Known hypersensitivity to meropenem or azithromycin * Coexisting infections requiring additional antimicrobial therapy * Chronic conditions including malnutrition or immunodeficiency * Congenital or acquired heart disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensively drug-resistant typhoid fever are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

typhoid fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensively drug-resistant typhoid fever Salmonella typhi infection Typhoid fever

Contacts and locations

Locations

  • Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan

    Rahim Yar Khan, Punjab Province, 64200, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.